Johnson & Johnson (NYSE:JNJ) had what on the surface appeared to be a pretty good quarter -- revenue and earnings were up solidly year-over-year, and the pharma business grew like a weed.
But looking under the surface, things didn't appear nearly as positive. And in the video below, Motley Fool health care analyst Michael Douglass lays out his concerns with Johnson & Johnson and what he thinks about this top dividend stock.
Alison Southwick owns shares of CVS Health. Michael Douglass owns shares of Johnson & Johnson and Gilead Sciences. The Motley Fool recommends CVS Health, Gilead Sciences, and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
How Much Do You Need to Save to Retire on Time and Send Your Kids to College?
See if you're in one of the lowest-cost states or if you should think about moving to one.
3 Great Reasons to Buy PayPal Holdings
This incredible growth story is just getting started.
Why NVIDIA Killed It in 2017
Heightened competition couldn't slow the graphics specialist's momentum.